An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer’s disease pathology following closed head injury: Evidence of pharmacogenomic interaction

@article{Wang2007AnAE,
  title={An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer’s disease pathology following closed head injury: Evidence of pharmacogenomic interaction},
  author={Hong-wei Wang and Lesley Durham and Hana N. Dawson and Pingfang Song and Daniel T Laskowitz},
  journal={Neuroscience},
  year={2007},
  volume={144},
  pages={1324-1333}
}
Apolipoprotein E (apoE) modifies glial activation and the CNS inflammatory response in an isoform-specific manner. Peptides derived from the receptor-binding region of apoE have been demonstrated to maintain the functional activity of the intact protein, and to improve histological and functional deficits after closed head injury. In the current study, APOE2, APOE3, and APOE4 targeted replacement (TR) mice expressing the human apoE protein isoforms (apoE2, apoE3 and apoE4) were used in a… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

New pharmacotherapy options for chemotherapy-induced alimentary mucositis.

  • Expert opinion on biological therapy
  • 2014
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Apolipoprotein E receptor pathways in Alzheimer disease.

  • Wiley interdisciplinary reviews. Systems biology and medicine
  • 2014

Similar Papers

Loading similar papers…